View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 30, 2021

Sanofi to invest $476m in mRNA vaccines facility

The centre will aid in expanding the mRNA vaccines portfolio developed through a collaboration with Translate Bio in 2018.

Sanofi is set to invest nearly $476m (€400m) a year in its new vaccines mRNA Center of Excellence, which will expedite the next-generation vaccines’ development and supply.

Free Report
img

How attractive are current investment opportunities in Europe?

Europe has been identified as one of the most favorable regions for investors, seeing high investment activity in the past year. Most of these investments have been through Debt Offering, valued at close to $700 billion. The region has provided attractive investments in a diverse set of companies. Companies who tend to major themes such Digital Media, Cloud, Artificial Intelligence, E-commerce, and Big Data are recording the highest number of deals, with Digital Media recording close to 2,000 deals. However, GlobalData’s whitepaper offers a full view of the market, analyzing less successful or attractive points of investment as well, examining statistics on Equity Offering investments and PE/VC deals. Understand how government agencies for economies around the world use GlobalData Explorer to:  
  • Track the M&A and Capital Raising volumes into their target market
  • Identify the top sectors in the target market attracting the investments
  • For any investment segment, identify the top Investors inside and outside the target economy that are already investing in the Segment
  • Assess and showcase the growth potential for various Industries in the target economy
Don’t miss out on key market insights that can help optimize your next investment – read the report now.
by GlobalData
Enter your details here to receive your free Report.

The facility will employ about 400 people.

Sanofi intends to combine the centre’s end-to-end messenger ribonucleic acid (mRNA) vaccine expertise with research and development (R&D), digital and chemistry, manufacturing and controls (CMC) teams at the Cambridge site in the US and Marcy l’Etoile site in Lyon, France.

The company noted that the latest development will aid in offering at least six clinical candidates by 2025.

The centre will help fast-track the mRNA vaccines portfolio created with Translate Bio under a partnership signed in 2018 and further expanded last year.

Apart from mRNA vaccines, the multi-year $855m deal focused on drugs for five infectious diseases.

Sanofi Pasteur global head and executive vice-president Thomas Triomphe said: “This massive new investment clearly puts us in the race to develop next-generation vaccines where mRNA technologies can have the greatest impact.

“While mRNA won’t be the solution for every infectious disease, its translation into routine prevention could have an immense impact for many unmet public health needs.”

In a separate development, Fujifilm has decided to invest approximately $850m (JPY90bn) to expand its core Bio contract development and manufacturing organisation unit, Fujifilm Diosynth Biotechnologies’ growth.

Fujifilm Diosynth Biotechnologies develops and produces recombinant proteins, vaccines, monoclonal antibodies, as well as various large molecules and viral products expressed in several microbial, mammalian and host/virus systems.

The investment will bolster Fujifilm Diosynth Biotechnologies’ production capability, doubling cell culture manufacturing for recombinant vaccines for Covid-19 in the US.

Fujifilm plans to boost gene therapy production by ten-fold and triple cell culture capacity while microbial fermentation output at the current 5,000L scale site will be doubled in the UK.

cGMP capacity for uninterrupted production will also be part of the UK cell culture expansion.

Process and analytical development capabilities will be included in the investment package, Fujifilm noted.

The expansions are slated to commence operations by late 2023.

Related Companies

Free Report
img

How attractive are current investment opportunities in Europe?

Europe has been identified as one of the most favorable regions for investors, seeing high investment activity in the past year. Most of these investments have been through Debt Offering, valued at close to $700 billion. The region has provided attractive investments in a diverse set of companies. Companies who tend to major themes such Digital Media, Cloud, Artificial Intelligence, E-commerce, and Big Data are recording the highest number of deals, with Digital Media recording close to 2,000 deals. However, GlobalData’s whitepaper offers a full view of the market, analyzing less successful or attractive points of investment as well, examining statistics on Equity Offering investments and PE/VC deals. Understand how government agencies for economies around the world use GlobalData Explorer to:  
  • Track the M&A and Capital Raising volumes into their target market
  • Identify the top sectors in the target market attracting the investments
  • For any investment segment, identify the top Investors inside and outside the target economy that are already investing in the Segment
  • Assess and showcase the growth potential for various Industries in the target economy
Don’t miss out on key market insights that can help optimize your next investment – read the report now.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology